I am John Snow Professor of Epidemiology at Queen Mary University of London. My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening.
My research activities are concentrated on cancer screening and early diagnosis. There is potential for considerable saving of lives from cancer if it were diagnosed at an earlier stage.
My research interests focus on improving the care of women with breast cancer through clinical trials. I am investigating a variety of novel agents that target specific pathways within cancer cells and the surrounding tissue.
My research is focused on Machine Learning with applications in Bioinformatics and Health Informatics, and Data Management of the Breast Cancer Now Tissue Bank (BCNTB).
My research focuses on understanding the progression of early breast cancer (ductal carcinoma in situ – DCIS) to invasive disease and the role of the microenvironment in this process.
My research is focused on understanding the early stages of breast cancer by using normal human breast cells obtained through the Breast Cancer Now tissue bank as building blocks to recreate a human breast duct in the laboratory environment.
My research focuses on understanding the role of RNA localisation in breast cancer progression. In particular, I am looking at how and why the cellular localization of some small nuclear RNAs (snoRNA) are altered during disease progression.
We are updating the bioinformatics data management system, expanding the analytical modules and functionalities, developing purpose-built graphical pug-ins and designing the bioinformatics infrastructure to allow the querying and analysis of data returned from projects using BCNTB tissues.
My research focuses on understanding the relationship between chromosome instability mechanisms and tumour cells’ resistance to therapies.
The aim of my work is to develop clinically-relevant biomarkers that could aid in earlier disease detection, predict treatment response, and inform clinical management of patients.
I am interested in understanding whether epigenetics can play a driving role in the transition from normal to transformed cells in the breast.
My research investigates a specific composition of extracellular matrix molecules which may explain the difference between responders and non-responders to immunotherapy.